On November 13th, 2025, Pfizer, Inc. closed a $10 billion transaction to acquire Metsera, Inc., a firm developing cutting-edge GLP-1 drugs for the treatment of obesity and type 2 diabetes.
Partners Jon Orszag, Dr. Jeremy Sandford, Dr. Dan Gaynor, along with Dr. James Banovetz, Dr. Josephine Xu, Joel Moore, Adam Rusakow, and Ishaan Goenka, advised Pfizer in connection with the antitrust litigation related to proposals made by Novo Nordisk, an incumbent manufacturer of GLP-1 drugs.
The Econic team worked closely with Pfizer’s counsel at Wachtell, Lipton, Rosen & Katz.
